Status:

UNKNOWN

Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19

Lead Sponsor:

Pirogov Russian National Research Medical University

Collaborating Sponsors:

Pfizer

Conditions:

Covid19

Eligibility:

All Genders

18+ years

Brief Summary

200 participants should be included in the study. There will be three groups: 100 participants with a severe course of the disease 3 months ago, 50 asymptomatic carriers of coronavirus infection 3 mon...

Eligibility Criteria

Inclusion

  • For all groups:
  • Informed consent signed by the patient.
  • Men and women aged 18 and over.
  • Group COVID-19 (asymptomatic):
  • Confirmed diagnosis of COVID-19 (positive SARS-CoV-2 RNA PCR test or history of IgM and / or IgG antibodies to SARS-CoV-2)
  • Absence of any clinical symptoms associated with coronavirus infection.
  • Group Healthy:
  • Contact with patients with symptomatic new coronavirus infection COVID-19 in the absence of personal protective equipment for at least 3 days.
  • Absence of any clinical symptoms associated with coronavirus infection
  • Group COVID symptomatic:
  • Confirmed diagnosis of previous COVID-19 (positive SARS-CoV-2 RNA PCR test or presence of IgM antibodies to SARS-CoV-2) in history.
  • A severe course of COVID-19, characterized by one or more of the following symptoms:
  • Respiratory rate ≥ 30 in 1 min
  • Blood oxygen saturation (SpO2) ≤ 93%
  • The ratio of the partial tension of oxygen in arterial blood to the fraction of oxygen during inspiration (PaO2 / FiO2) \<300
  • Lung tissue lesion\> 50% and / or according to computed tomography CT-2 and higher
  • Septic shock / sepsis
  • Development of multiple organ failure
  • Cytokine storm

Exclusion

  • Pregnancy
  • Covid-19 vaccination
  • Any serious medical illness before coronavirus infection, as well as a permanent form of atrial fibrillation
  • Regular intake of anti-inflammatory, antibacterial, cytostatic and immunosuppressive drugs
  • Refusal to participate in the study

Key Trial Info

Start Date :

January 20 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 15 2021

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04871789

Start Date

January 20 2021

End Date

June 15 2021

Last Update

May 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Russian Clinical Research Center for Gerontology

Moscow, Russia, 129226